<div id="readability-page-1"><p>Frontier Asset Management LLC lowered its holdings in shares of  AbbVie Inc. (NYSE:ABBV - Free Report) by 50.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 12,415 shares of the company's stock after selling 12,545 shares during the period. Frontier Asset Management LLC's holdings in AbbVie were worth $2,837,000 as of its most recent SEC filing.</p><ul><li>The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat</li></ul><p>Several other hedge funds have also recently added to or reduced their stakes in ABBV. Vanguard Group Inc. raised its stake in shares of  AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after buying an additional 3,032,438 shares in the last quarter.  Legal &amp; General Group Plc raised its stake in shares of  AbbVie by 4.3% in the 3rd quarter. Legal &amp; General Group Plc now owns 12,004,084 shares of the company's stock worth $2,779,426,000 after buying an additional 493,420 shares in the last quarter.  Wellington Management Group LLP raised its position in shares of  AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the period.  Amundi raised its position in shares of  AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares during the period.  Finally, Ameriprise Financial Inc. raised its position in shares of  AbbVie by 4.4% during the third quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock worth $2,241,363,000 after purchasing an additional 408,426 shares during the period. Institutional investors own  70.23% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities research analysts have recently issued reports on the company. DZ Bank raised AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, April 30th. Berenberg Bank  set a $275.00 target price on AbbVie in a research report on Tuesday, January 20th. Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday, January 27th. Piper Sandler lowered their price target on AbbVie from $299.00 to $294.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, April 23rd. Finally, Evercore lowered their price target on AbbVie from $232.00 to $228.00 and set an &#34;outperform&#34; rating on the stock in a report on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned  a Buy rating and six have assigned  a Hold rating to the company's stock. According to MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $252.90.</p><ul><li>MarketBeat Week in Review – 04/27 - 05/01</li></ul><p><b>Get Our Latest Report on ABBV</b></p><h2>AbbVie Trading Down 0.7%</h2><p>Shares of ABBV stock opened at $201.24 on Friday. The stock's fifty day simple moving average is $213.18 and its 200-day simple moving average is $221.00. AbbVie Inc. has a 1-year low of $176.57 and a 1-year high of $244.81. The company has a market capitalization of $355.83 billion, a price-to-earnings ratio of 99.13, a P/E/G ratio of 0.70 and a beta of 0.32. </p><ul><li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the company posted $2.46 earnings per share. The business's quarterly revenue was up 12.4% compared to the same quarter last year.  On average, sell-side analysts predict that  AbbVie Inc. will post 14.32 EPS for the current year. </p><h2>AbbVie Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie's payout ratio is 340.89%. </p><h2>Key Stories Impacting AbbVie</h2><p>Here are the key news stories impacting AbbVie this week:</p><ul>   <li><span>Positive Sentiment: </span>AbbVie continued to draw bullish attention after reporting strong first-quarter results, with revenue and earnings coming in ahead of expectations and showing that growth is extending beyond Humira into newer drugs like Skyrizi and Rinvoq. <i></i><span>AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.</span></li>   <li><span>Positive Sentiment: </span>AbbVie completed an early safety study for ABBV-142, which may improve investor confidence in the company’s pipeline and future oncology growth prospects. <i></i><span>AbbVie Completes Early Safety Study for ABBV-142, Nudging Pipeline Hopes Higher</span></li>   <li><span>Positive Sentiment: </span>AbbVie and adMare BioInnovations named RIME Therapeutics as a Biotech Innovators Award winner, reinforcing AbbVie’s efforts to support early-stage biotech innovation and build optionality around its pipeline ecosystem. <i></i><span>AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner</span></li>   <li><span>Positive Sentiment: </span>Skyrizi ranked ahead of J&amp;J’s Tremfya in April drug ad spending, signaling continued competitive momentum and heavy marketing support for one of AbbVie’s key growth brands. <i></i><span>AbbVie’s Skyrizi beats out J&amp;J’s Tremfya in April drug ad spending leaderboard</span></li>   <li><span>Neutral Sentiment: </span>Analyst commentary and Q1 earnings-call recaps highlighted ongoing interest in AbbVie’s post-Humira growth strategy, but these pieces were mostly interpretive rather than new market-moving disclosures. <i></i><span>5 must-read analyst questions from AbbVie’s Q1 earnings call</span></li>   <li><span>Neutral Sentiment: </span>Coverage on SKYRIZI expansion and reimbursement progress in Canada suggests continued international adoption, but the article framed these as part of an already constructive longer-term thesis rather than a single new catalyst. <i></i><span>Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?</span></li>   <li><span>Negative Sentiment: </span>One relative headwind is that ABBV shares have recently traded below key moving averages, reflecting some investor caution even as fundamentals remain solid. </li> </ul><h2>Insider Transactions at AbbVie</h2><p>In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders own  0.06% of the company's stock. </p><h2>AbbVie Company Profile</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than AbbVie</li><li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li><li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li><li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li><li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Frontier Asset Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 50.3% in Q4, according to a recent SEC filing. After selling 12,545 shares, it now owns 12,415 shares valued at approximately $2.84 million. Other institutional investors, including Vanguard and Legal & General, have increased their stakes in AbbVie. The stock opened at $201.24, with a market cap of $355.83 billion. AbbVie recently reported earnings of $2.65 per share, exceeding estimates, and announced a quarterly dividend of $1.73, yielding 3.4%.</p>

Market Beat

Abbvie

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VG Health

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares US Pharma

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Legal & General Group Plc

Ameriprise Financial

Citigroup

Piper Sandler Cos

Evercore

CITIGROUP INC 6.250 NON CUM SER II PFD WI

AbbVie Inc. $ABBV Stock Holdings Trimmed by Frontier Asset Management LLC